EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma

Jinhai Zou, Han Zou, Chang Liu, Chen Liang, Yufei Liang, Meiyu Zheng, Chunying Li

Frontiers in Oncology · 24.08.2026 · 16

DOI: 10.3389/fonc.2026.1856758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 24.08.2026. Verfasst von Jinhai Zou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Cangzhou Central Hospital, Cangzhou, Hebei, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common and highly heterogeneous subtype of non-Hodgkin lymphoma, and accurate staging is essential for treatment planning and prognosis. This study explored the value of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) metabolic network connectivity for the clinical staging of DLBCL.

Methods

Forty-two previously untreated patients (23 males, 19 females; aged 30-82 years) diagnosed as de novo DLBCL, not otherwise specified, were retrospectively analyzed (stage I, n=3; II, n=5; III, n=9; IV, n=25). Lesions were automatically delineated using a 41% SUVmax threshold. Four metabolic and four diffusion parameters were computed, and a radiomics-based lesion metabolic network was constructed for each patient with stage II-IV disease.

Results

The degree Pearson correlation coefficient (DPCC) of the metabolic network differed significantly among stages II-IV (n=39, p<0.001) and between stage II (n=5) and stages III+IV (n=34) (p<0.001), whereas conventional metabolic, diffusion, and other network parameters showed no significant differences. DPCC decreased with increasing stage, indicating rising inter-lesion metabolic heterogeneity.

Discussion

The DPCC of 18F-FDG PET/CT metabolic network connectivity is associated with clinical stage in DLBCL patients with multiple measurable lesions and may provide complementary network-level information. These exploratory findings require external validation in larger, multicenter cohorts.

Schlagwörter

Stichwörter der Autor:innen

18F-FDG PET/CTdiffuse large B-cell lymphomalymphoma clinical stagelymphoma diffusion parametersmetabolic network connectivity

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Cangzhou Central Hospital, Cangzhou, Hebei, China.
  • Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
  • Department of Gastroenterology III, Cangzhou Central Hospital, Cangzhou, Hebei, China.

Zitieren

APA

Zou, J., Zou, H., Liu, C., Liang, C., Liang, Y., Zheng, M., & Li, C. (2026). 18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1856758

Vancouver

Zou J, Zou H, Liu C, Liang C, Liang Y, Zheng M, et al. 18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1856758

BibTeX
@article{Zou2026,
  author = {Zou, Jinhai and Zou, Han and Liu, Chang and Liang, Chen and Liang, Yufei and Zheng, Meiyu and Li, Chunying},
  title = {18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1856758}
}
Kostenlos starten →